Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ESG 401

Next Previous
Drug Profile

ESG 401

Alternative Names: ESG-401; OQY-3258; STI-3258

Latest Information Update: 27 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shanghai Escugen Biotechnology
  • Class Antibodies; Antineoplastics; Camptothecins; Drug conjugates; Immunoconjugates; Indolizines; Monoclonal antibodies; Pyrans; Quinolines; Recombinant fusion proteins
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Breast cancer; Triple negative breast cancer
  • Phase I/II Solid tumours

Most Recent Events

  • 17 Oct 2025 Updated efficacy and adverse events data from the phase I/II trial in Solid tumours presented at the 50th European Society for Medical Oncology Congress (ESMO-2025)
  • 30 Jun 2025 Vincerx Pharma completes a phase I/II trial in Solid tumour in China (IV) (NCT04892342)
  • 29 Jan 2025 Phase-III clinical trials in Triple-negative-breast-cancer (Metastatic disease, Inoperable/Unresectable, First-line therapy, Recurrent) in China (IV), ,

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top